Banco Santander SA ADR

Yahoo Finance • 2 days ago

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a nove... Full story

Yahoo Finance • 3 days ago

Fortune Reveals the 100 Most Powerful Women in Business 2026 List

Jane Fraser, Chair and CEO of Citigroup, leads Fortune's 29th annual Most Powerful Women in Business list Women driving change across AI, finance, energy, and health care are among this year's top honorees Half of the women on the list r... Full story

Yahoo Finance • 9 days ago

Blackstone Digital Infrastructure Trust Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares in Initial Public Offering

NEW YORK, May 20, 2026--(BUSINESS WIRE)--Blackstone Digital Infrastructure Trust Inc. (NYSE: BXDC) (the "Company") today announced that, in connection with its previously announced initial public offering, the underwriters have exercised t... Full story

Yahoo Finance • 15 days ago

HSBC puts $4bn shadow banking drive on hold amid crisis fears

HSBC had previously used shadow banking as a way to muscle into the territory of private credit giants - Andy Rain /Shutterstock HSBC has slammed the brakes on its $4bn (£3bn) shadow banking drive amid fears of a crisis in the unregulated... Full story

Yahoo Finance • 17 days ago

UK Cards and Payments Market Insights 2021-2025 and Growth Outlook 2026-2030 Featuring Lloyds Banking Group, NatWest Group, Barclays, HSBC, Santander and More

Company Logo Key market opportunities include the rise of e-commerce, growth of open banking with Paytently and Mastercard's collaboration, and increasing popularity of contactless payments exemplified by Edinburgh's Tap-on, Tap-off syste... Full story

Yahoo Finance • 22 days ago

Jim Cramer Says “Buy Banco Santander”

Banco Santander, S.A. (NYSE:SAN) was one of the stocks on Jim Cramer’s radar as he highlighted AI winners to buy for 2026. Highlighting the company’s “record-breaking quarter,” a caller asked if Cramer is still bullish on the stock and whe... Full story

Yahoo Finance • 23 days ago

Santander to drop UK’s TSB name after takeover

Santander is preparing to remove the TSB name from Britain’s high streets following its acquisition of the UK retail bank, ending a brand history that stretches back more than 215 years, reported Financial Times citing sources. The Spanis... Full story

Yahoo Finance • 23 days ago

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Company Logo Global IgG4-related disease market sees growth due to increased research funding and development of targeted therapies. This rare autoimmune condition results in inflammation and organ dysfunction. Emerging biologic treatment... Full story

Yahoo Finance • 25 days ago

ElevenLabs lists BlackRock, Jamie Foxx and Longoria as new investors

LONDON, ENGLAND - JUNE 04: Mati Staniszewski speaks onstage during "The AI Voice Revolution" panel discussion on day three of SXSW London 2025 at the Truman Brewery on June 04, 2025 in London, England. (Photo by Jeff Spicer/Getty Images fo... Full story

Yahoo Finance • 25 days ago

HSBC Results Disappoint With Surprise $400 Million Charge on MFS

(Bloomberg) -- HSBC Holdings Plc reported profit that missed estimates, weighed down by an unexpected charge related to the collapse of UK mortgage lender Market Financial Solutions Ltd. and rising economic risks stemming from the conflict... Full story

Yahoo Finance • 26 days ago

Santander UK closes £2.65bn purchase of TSB from Sabadell

Santander UK has completed its purchase of TSB from Sabadell, after the clearance from the Prudential Regulation Authority and the European Central Bank. The cash deal, which was initially signed in July 2025 and valued at £2.65bn ($3.6bn... Full story

Yahoo Finance • 29 days ago

Sanofi (ENXTPA:SAN) Valuation After Cenrifki Progress New CEO Appointment And Stronger Dupixent Momentum

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why Sanofi’s recent news flow matters for shareholders Sanofi (ENXTPA:SAN) has packed several key updates into late April,... Full story

Yahoo Finance • 30 days ago

Banco Santander SA (SAN) Q1 2026 Earnings Call Highlights: Record Profit and Strong Capital Position

This article first appeared on GuruFocus. Profit: EUR3.6 billion, up 12% versus Q1 '25. Efficiency Improvement: Improved by 3 percentage points. Underlying RoTE: Increased to 15.2%. CET1 Capital Ratio: Reached 14.4%, an all-time high. Rev... Full story

Yahoo Finance • last month

Banco Santander Q1 Earnings Call Highlights

Banco Santander logo 3 European Bank Stocks Nearing New 52-Week Highs Banco Santander (NYSE:SAN) opened its first-quarter 2026 results presentation by highlighting that it is the first quarter reported after the disposal of Santander Pol... Full story

Yahoo Finance • last month

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics

Company Logo The Germany Anemia Treatment Market is set to reach USD 1.05 billion by 2034, growing at a CAGR of 6.84% from USD 581.344 million in 2025. This growth is driven by an aging population, increased iron-deficiency cases, and the... Full story

Yahoo Finance • last month

Oncology Clinical Trials Research Report 2026: $20+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology clinical trials market has seen substantial growth, transitioning from $14.9... Full story

Yahoo Finance • last month

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3Tzield is the first disease-modif... Full story

Yahoo Finance • last month

Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants

Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 de stade 2 pour re... Full story

Yahoo Finance • last month

Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis

Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis Paris, le 22 avril 2026. La Food and Drug Administration (FDA) des États-Unis a prolongé de jusqu’à trois mois la date cible d'act... Full story

Yahoo Finance • last month

Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe  

ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe Première étude comparative de phase 4, randomisée, en double aveugle, permettant de comparer... Full story